Aburaihan Pharmaceutical Company, founded in 1964 under the name Berlimed Iran, has established itself as a leader in the production of human and veterinary medicines in Iran. With over 56 years of experience, the company transitioned to a public joint stock entity in 1991, reinforcing its commitment to quality and innovation. Aburaihan offers a diverse range of over 200 pharmaceuticals, specializing in sectors such as cardiology, neurology, oncology, and women's health, along with a variety of dietary supplements.

The company places a strong emphasis on research and development, employing advanced technologies and adhering to international standards set forth by GXP and WHO. With a dedicated team of over 500 skilled professionals, Aburaihan is not only focused on medication production but also on providing marketing, trading, and research services. Their mission is to enhance public health while maintaining a robust social responsibility ethos.

As one of Iran's largest pharmaceutical manufacturers, Aburaihan plays a crucial role in the advancement of the country's healthcare industry